Full text loading...
View Affiliations Hide Affiliations
FN1Financial support: This work was supported by grants 2011/20484-7 and 2015/09080-2, São Paulo Research Foundation (FAPESP), grant 473343/2012-6, Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), and Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES). CRE (2015/05130-5) and ACC (2012/14629-5) were supported by FAPESP fellowships. SRBU and EMC receive senior researcher scholarships from CNPq. FR-D is a research fellow of CNPq.
FN2Authors' addresses: Caroline R. Espada, Jenicer K. U. Yokoyama-Yasunaka, and Silvia R. B. Uliana, Laboratório de Leishmanioses, Departamento de Parasitologia, Instituto de Ciências Biomédicas, Universidade de São Paulo, São Paulo, Brazil, E-mails: firstname.lastname@example.org, email@example.com, and firstname.lastname@example.org. Fátima Ribeiro-Dias, Miriam L. Dorta, and Ledice Inácia de Araújo Pereira, Laboratório de Imunobiologia das Leishmanioses, Instituto de Patologia Tropical e Saúde Pública, Universidade Federal de Goiás, Goiânia, Brazil, E-mails: email@example.com, firstname.lastname@example.org, and email@example.com. Edgar M. de Carvalho, Paulo R. Machado, and Albert Schriefer, Serviço de Imunologia, Faculdade de Medicina, Universidade Federal da Bahia, Salvador, Brazil, E-mails: firstname.lastname@example.org, email@example.com, and firstname.lastname@example.org. Adriano C. Coelho, Departamento de Biologia Animal, Instituto de Biologia, Universidade Estadual de Campinas, Campinas, Brazil, E-mail: email@example.com.
- The American Society of Tropical Medicine and Hygiene,
- Source: The American Journal of Tropical Medicine and Hygiene, Volume 96, Issue 3, Mar 2017, p. 656 - 659
Susceptibility to Miltefosine in Brazilian Clinical Isolates of Leishmania (Viannia) braziliensis
Leishmania (Viannia) braziliensis is the main causative species of tegumentary leishmaniasis in Brazil. In this study, we evaluated the susceptibility of 16 clinical isolates of L. (V.) braziliensis from different regions of Brazil to miltefosine in vitro. Half-maximal inhibitory concentrations of miltefosine varied from 22.9 to 144.2 μM against promastigotes and from 0.3 to 4.2 μM against intracellular amastigotes. No significant differences were found between isolates of different geographical origins. A clear correlation between the EC50 against promastigotes and amastigotes within each isolate was found. These findings contribute to the evaluation of miltefosine's potential and limitations for the treatment of tegumentary leishmaniasis in Brazil.